NSTG - NanoString Technologies, Inc.
| Previous Close | 27.57 |
| Open | 27.99 |
| Bid | 0.00 x 900 |
| Ask | 0.00 x 1400 |
| Day's Range | 27.51 - 28.58 |
| 52 Week Range | 13.26 - 34.78 |
| Volume | 304,199 |
| Avg. Volume | 558,347 |
| Market Cap | 1.001B |
| Beta (3Y Monthly) | 1.40 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.50 |
| Earnings Date | Nov 6, 2019 - Nov 11, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 37.50 |
- GlobeNewswire
NanoString to Present at the Baird 2019 Global Healthcare Conference
SEATTLE, Aug. 19, 2019 -- NanoString Technologies, Inc. (NASDAQ:NSTG), a leading provider of life science tools for translational research and molecular diagnostic products,.
- GuruFocus.com
Nanostring Technologies Inc (NSTG) President and CEO R Bradley Gray Sold $993,600 of Shares
President and CEO of Nanostring Technologies Inc (30-Year Financial, Insider Trades) R Bradley Gray (insider trades) sold 40,000 shares of NSTG on 08/12/2019 at an average price of $24.84 a share. Continue reading...
- GuruFocus.com
Nanostring Technologies Inc (NSTG) CFO K Thomas Bailey Sold $899,175 of Shares
CFO of Nanostring Technologies Inc (30-Year Financial, Insider Trades) K Thomas Bailey (insider trades) sold 35,625 shares of NSTG on 08/06/2019 at an average price of $25.24 a share. Continue reading...
- GlobeNewswire
New Publication Demonstrates First Use of NanoString’s GeoMx Digital Spatial Profiler in Neuroscience
NanoString Technologies, Inc. (NSTG), a provider of life science tools for translational research and molecular diagnostic products, today announced the publication of a study in the journal Acta Neuropathologica that demonstrates the capability of the GeoMx™ Digital Spatial Profiler (DSP) to characterize the microenvironment surrounding beta-Amyloid plaques in the brains of Alzheimer’s disease (AD) patients.
- Thomson Reuters StreetEvents
Edited Transcript of NSTG earnings conference call or presentation 31-Jul-19 8:30pm GMT
Q2 2019 NanoString Technologies Inc Earnings Call
- Motley Fool
NanoString Technologies Delivers 21% Revenue Growth in Q2
All eyes were on a new instrument launch, which got off to a strong start judging from pre-orders.
Motley FoolNanostring Technologies (NSTG) Q2 2019 Earnings Call Transcript
NSTG earnings call for the period ending June 30, 2019.
- Zacks
NanoString Technologies (NSTG) Reports Q2 Loss, Tops Revenue Estimates
NanoString (NSTG) delivered earnings and revenue surprises of -3.64% and 4.64%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
- GlobeNewswire
NanoString Technologies Releases Operating Results for Second Quarter of 2019
SEATTLE, July 31, 2019 -- NanoString Technologies, Inc. (NASDAQ:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today.
- GlobeNewswire
NanoString Technologies and Mayo Clinic Laboratories Enter Joint Development Agreement to Develop Novel Assays
SEATTLE and ROCHESTER, Minn., July 30, 2019 -- NanoString Technologies and Mayo Clinic Laboratories have announced a collaboration to develop clinical tests using NanoString's.
- American City Business Journals
Need to know: Why investors target Washington banks, the soul of South Lake Union and the Trump Island mansion burns down
Business Journal Managing Editor Rob Johnson recaps the week in Seattle business news, including an overview of why Washington banks have been targeted in proxy battles, how Boeing is dealing with a rough second quarter and much more. Catch up on all the Seattle-area business news you may have missed.
- Zacks
Will NanoString Technologies (NSTG) Report Negative Earnings Next Week? What You Should Know
NanoString (NSTG) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- GlobeNewswire
CORRECTING and REPLACING - Nature Medicine Publication Highlights use of the GeoMx Digital Spatial Profiler to Characterize Mechanism of Neurotoxicity in Immuno-Therapy
In a release issued yesterday by NanoString Technologies, Inc. (NSTG) under the same headline, please note that in the third paragraph Dr. Justin Balko's title has been revised. While checkpoint inhibitors can lead to durable responses in a range of metastatic cancers, unanticipated immune-related adverse events can limit the utility of these life-saving therapies.
- Simply Wall St.
Is NanoString Technologies, Inc. (NASDAQ:NSTG) A Financially Sound Company?
Investors are always looking for growth in small-cap stocks like NanoString Technologies, Inc. (NASDAQ:NSTG), with a...
- GlobeNewswire
Nature Medicine Publication Highlights use of the GeoMx Digital Spatial Profiler to Characterize Mechanism of Neurotoxicity in Immuno-Therapy
While checkpoint inhibitors can lead to durable responses in a range of metastatic cancers, unanticipated immune-related adverse events can limit the utility of these life-saving therapies. A group of researchers lead by Dr. Justin Balko recently published a study entitled “A case report of clonal EBV-like memory CD4+ T cell activation in fatal checkpoint inhibitor induced encephalitis.” In this case report, investigators used the GeoMx DSP to characterize immune infiltrates in the brain of a patient who passed away from neurotoxicity following immunotherapy treatment for metastatic melanoma.
- Motley Fool
What to Watch When NanoString Technologies Reports Q2 Results
Investors will be focused on a potentially trajectory-altering product launch, but it will be several quarters (at least) before we can start drawing conclusions about its impact.
- GlobeNewswire
NanoString Collaborates with MODEL-AD Consortium to Accelerate Alzheimer’s Disease Research
nCounter Mouse AD Gene Expression Panel Applied to Characterize Five Novel Mouse Models New nCounter Human AD Gene Expression Panel Launched at AAIC 2019 SEATTLE, July.
- Motley Fool
Here's Why NanoString Technologies Stock Soared 104.7% in the First Half of 2019
Investors are excited (perhaps a little too excited) about a new opportunity in immuno-oncology.
- GlobeNewswire
NanoString to Release Second Quarter 2019 Financial Results and Host Conference Call on Wednesday, July 31, 2019
SEATTLE, July 10, 2019 -- NanoString Technologies, Inc. (NASDAQ:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today.
- Insider Monkey
Hedge Funds Have Never Been This Bullish On NanoString Technologies Inc (NSTG)
As we already know from media reports and hedge fund investor letters, many hedge funds lost money in fourth quarter, blaming macroeconomic conditions and unpredictable events that hit several sectors, with technology among them. Nevertheless, most investors decided to stick to their bullish theses and recouped their losses by the end of the first quarter. […]
- GlobeNewswire
Publication in the Journal Clinical Cancer Research Uses NanoString’s GeoMx Digital Spatial Profiler to Discover Predictive Biomarkers for Immunotherapy
NanoString Technologies, Inc. (NSTG), a provider of life science tools for translational research and molecular diagnostic products, today announced a publication in the journal Clinical Cancer Research of a collaborative research study led by investigators from the Yale School of Medicine. This paper represents the fourth peer-reviewed publication to describe GeoMx DSP.
- Simply Wall St.
Have Insiders Been Selling NanoString Technologies, Inc. (NASDAQ:NSTG) Shares?
It is not uncommon to see companies perform well in the years after insiders buy shares. The flip side of that is that...
- American City Business Journals
These Washingtonians have donated the most to Gov. Inslee's presidential run
Gov. Inslee has raised $2.3 million this year, with more than $1 million of that coming from donors in the Evergreen State.
- GlobeNewswire
NanoString Partners with Multiple Leading Contract Research Organizations to Provide Standardized PanCancer IO 360 Data Analysis Reports
SEATTLE, May 30, 2019 -- NanoString Technologies, Inc. (NASDAQ:NSTG), a leading provider of life science tools for translational research and molecular diagnostic products,.
